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ABST RACT
The screening for pre-invasive cervical lesions has significantly decreased
the incidence of cervical neoplasm. It is recommended to be performed
starting with the age of 21 with a frequency of 3-5 years and it consists of
pap smear testing and HPV genotyping, and, if required, it can be continued
with colposcopy or biopsy followed by pathological assessment. The
importance of the early diagnosis of pre-invasive cervical lesions has led to
several studies on this topic. The paper analyzed the modern literature
published on the PubMed and Scopus databases. Reference studies have
found that most intraepithelial lesions are caused by the presence of HPV.
Other commonly associated factors are immunosuppression, multiparity and
other viral infections. HPV infection can be prevented by vaccination. It is
recommended for people between 11 and 26 years old and also over 27 years
old if they associate risk factors. A meta-analysis performed on patients
diagnosed with CIN2 revealed a lower recurrence rate in vaccinated women
than in unvaccinated women. Other studies have shown the transient nature
of HPV infection and spontaneous regression of pre-invasive lesions. The
early diagnosis of pre-invasive lesions is necessary for the initiation of
therapeutic and follow-up behavior as soon as possible, with the aim of
reducing the incidence of cervical cancer. This is possible and easy to access
through national health programs.

Introduction
The early diagnosis of pre-invasive cervical lesions has
been a challenge since the twentieth century. National
screening programs have been developed to reduce the
incidence of cervical cancer, but this pathology remains a
public health problem. In the United States, the incidence
of malignant tumor pathology of the cervix has decreased
since the 1970s, after the evolution of the first national
screening programs [1,2].
Intraepithelial cervical lesions (CIN) are premalignant
lesions of non-keratinized multilayered epithelial covering
tissue [3]. The cervix consists of endocervix (cylindrical
epithelium) and exocervix (squamous epithelium). The
screening for pre-invasive and invasive cervical lesions
includes Pap smear and HPV genotyping. Depending on the
results, these investigations can be completed with
colposcopic examination and pathological assessment [4,5].
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In order to be able to diagnose these lesions at an early
stage, every woman older than 21 years old has to undergo
screening tests: Papanicolau smear (Pap smear) once every
three years, or HPV genotyping together with Pap smear
every 5 years [6,7].
Pap smear examines cervical cellularity, thus being able
to diagnose malignant intraepithelial lesions, inflammation,
atrophy, or other physiological and pathological changes in
the cervical epithelium [8,9]. On the referral note of the
cytological examination, one must specify the date of the last
menstruation, the presence of intrauterine devices and
pregnancy [10]. HPV genotyping seeks to multiply the HPV
genome to identify viral strains [11].
For the diagnosis of intraepithelial cervical lesions, the
colposcopic examination is also used, which analyzes the
modifications of the external layer of the cervix and of the
squamous-columnar junction. The investigation is
indicated in case of unfavorable results at Pap smear
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examination or HPV genotyping [12]. During the
colposcopic examination, a tissue fragment can be
collected for the histopathological examination. This
procedure does not require the hospitalization of the
patient and it has few contraindications: cervicitis,
hemorrhagic diathesis, vaginal bleeding, pregnancy and
immunosuppression [13,14].
The next step in the diagnosis of the lesions is the
pathological evaluation. Conization together with the
diathermic loop electro resection and bioptome biopsy are
reliable methods that provide tissue for the
histopathological examination. Uterine curettage is not a
routine indication if conization is performed. It is indicated
only if there are glandular cell abnormalities on Pap smear
or if they have risk factors for endometrial hyperplasia or
endometrial adenocarcinoma [15].
The literature search was conducted in PubMed and
Scopus databases using the terms “Cervical intraepithelial
lesions”, “excisional procedures” and “screening and
diagnostic for cervical lesions”. No date restriction was
applied. Language was restricted to English and French.
Additional studies from the reference list of the articles
were searched.

Discussions
CIN occurs most frequently in the squamous-columnar
junction, being secondary to the HPV infection. Most
intraepithelial lesions are thought to be caused by HPV, but
not all HPV infections cause CIN [16,17]. Besides the HPV
infection, other risk factors are immunosuppression, diet,
multiparity, first delivery before the age of 17 years,
multiple sexual partners, lack of condom use, smoking,
herpes virus infection. A study conducted by Anttila
revealed that Chlamydia trachomatis has an implication in
the development of pre-invasive lesions [18-21]. A study
conducted by Aldieh revealed how a person living with
HIV is affected by the co-infection with HPV. If left
untreated, the HIV infection decreases the number of CD4
positive lymphocytes. On the other hand, an HIV positive
undetectable person has a pro-inflammatory status [22].
Another important exponent is smoking, which releases
nicotine-derived ketones that lead to decreased local
immunity [23].
The HPV infection is a sexually transmitted infection,
and 75-80% of sexually active people have had the
infection. Its natural evolution has several stages: latent
infection
(minimal
clinical,
colposcopic
and
histopathological changes) is the most common form of
HPV infection. Active infection, without genomic
integration (the virus replicates intensely, cell nuclei
become large, multinucleated and hyperchromatic with a
halo around the nucleus) corresponds to low-grade lesions
(L-SIL) on the cytological evaluation. The evolution at this
stage depends on the host's immune system. Antibodies
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directed against viral particles are produced by CD4 + T
lymphocytes and macrophages. Most people produce these
antibodies efficiently, so the evolution is favorable.
The last stage in the evolution of the infection is the
genomic integration, which corresponds to the malignant
tumor pathology [24-28].
Clinical presentation
Intraepithelial lesions do not have a characteristic
symptomatology, most often we encounter abnormal
vaginal bleeding, changes in bowel movement, changes in
bladder function, pelvic pain syndrome, dyspareunia,
macroscopic lesions on the exocervix [29-31].
Paraclinical evaluations
The diagnosis of pre-invasive cervical lesions uses
multiple paraclinical evaluations.
Pap smear
Pap smear examines cervical cellularity for abnormal
cells. It is a screening method that must be done every three
years. The appearance of a lesion on a properly performed
screening is very small: 10-> 66 / 10,000. It is not
recommended to be performed annually, as it does not
decrease the risk of death from cervical cancer. A study
conducted by Sawaya et al. covering patients aged 21 to 29
years revealed that the risk of death from cervical cancer is
identical, regardless of whether the cytological evaluation
is done at one, two or three years [6,10,32].
The evaluation is not done during menstruation. It is
important not to touch the exocervix when inserting the
vaginal speculum, as dysplastic cells can attach to the
speculum. Although during menstruation it is
recommended not to perform the examination, it should not
be delayed in case of cervicorrhagia, metrorrhagia or
abnormal secretion because they can be symptoms of a
malignant pathology of the cervix.
On the referral note of the cytological examination, it
is important to mention the date of the last menstruation,
because the appearance of the vaginal and cervical
epithelium varies with the ovarian cycle. Another thing to
mention is pregnancy, exogenous hormone therapy,
metrorrhagia, a history of dysplastic lesions, menopause,
the use of intrauterine devices (IUD). In the case of IUD,
it is recommended to take cells from the anterior vaginal
wall as well, as these patients have an increased risk of
developing vaginal cancer [33]. The Bethesda 2014
classification is used to provide the cytological result.
Intraerpithelial lesions are subdivided into several
groups. Squamous cell atypia-like lesions (AUC): lesions
of determined significance (AUC-US) or lesions that
cannot rule out a high-grade lesion (AUC-H). Low-grade
lesions L-SIL include CIN 1, HPV infection, mild
dysplasia. High-grade lesions: H-SIL include severe,
moderate dysplasia, CIN2, CIN3, carcinoma in situ and
the invasive lesion represents squamous cell carcinoma of
the cervix [34,35].
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The HPV genotyping can be done alone or together
with Pap smear once every 5 years. The most common
strains 16, 18 are routinely tested on the cytological
examination. It is useful to do it alone in patients who do
not have access to screening services [11,34,36].
Colposcopy
Colposcopy is used to evaluate the cervix. It is
indicated in case of macroscopically visible genital tract
lesions, abnormal cytological evaluation, positive HPV
evaluation, intrauterine exposure to diethylstilbestrol,
unexplained genital tract bleeding [12,33]. The
examination can confirm if one has vulgar warts, cervicitis,
pre-invasive lesions of the cervix, vagina or vulva.
It has few risks; it allows the biopsy to be performed.
Among the risks that arise after tissue sampling are:
bleeding, infection and pelvic pain syndrome. Preprocedural training includes: no sexual intercourse 24-48
hours before, no intravaginal tampons should be used 1-2
days before, no intravaginal medication and no
menstruation [37,38]. The examinations that are
performed: the native macroscopic evaluation of the
cervix, the examination with 3-5% acetic acid, which stains
the aceto-white lesions, the Lahm-Schiller test using lugol.
Normal cells have estrogen receptors; thus, those cells have
glycerol in their cytoplasm. On the other hand, dysplastic
cells lack these receptors and they have a lower quantity of
glycerol. The last evaluation on colposcopy finds
dysplastic cells using Lugol (an iodine solution). If the
cells have glycerol, iodine will impregnate them. The last
stage is omitted in the case of patients allergic to iodine or
contrast agents. The results that suggest a cervical lesion
are: acetone-white epithelium, mosaic, punctures and
leukoplakia.
The study conducted by Sophia S. analyzed the
incidence of malignant tumor subtypes located in the
cervix, and as a result of the screening programs, the
incidence of squamous cell carcinoma of the cervix is
decreasing, but the lack of experience in endocervical cell
evaluation has led to an increase of endocervical
adenocarcinomas [12,33].
Conization
There are also invasive diagnostic methods: conization
with the cold scalpel, conization with the electrocautery or
excision with the diathermic loop.
Conization with the cold scalpel offers a good piece for
histopathological evaluation, it is simple, it requires
general or local anesthesia, but it has a higher complication
rate than other methods [39]. The patient is placed in a
lithotomy position, the vaginal speculum is mounted, the
colposcopic evaluation or Lugol can be used to observe the
areas with lesions. Two sutures can be made at 3 and 9
o'clock to limit bleeding. Sometimes it is useful to inject
vasopressors which lead to a decrease in the intraoperative
bleeding, in the absence of contraindications

(hypertension). A circumferential incision is made that
goes as deep as possible, it is excised and the neck is
restored with Strumdorf suture [33].
Conization with the electrocautery offers a good
specimen, good hemostasis and it has a lower complication
rate, but it is more difficult, it can cause thermal damage in
the adjacent structures, it is difficult to make a small radius
cone [39-41].
The loop electrosurgical excision procedure is easy,
fast, has few complications and provides a good piece for
histopathological examination, but it can cause thermal
damage to adjacent tissues and it is difficult to perform for
a large area of tissue. Lidocaine can be used for local
anesthetic purposes, but also to limit bleeding. It penetrates
the cervix with a loop and in a single movement a fragment
of the cervix is excised and sent for the histopathological
examination [33,39,42].
A study conducted by Hu X looked at the rate of HPV
infection among medical staff practicing electrocautery or
diathermic excision. Procedures that lead to smoke
generation are dangerous for doctors and nurses because
they expose them to HPV that will be found to the nasal
epithelium (the incidence is 9-10% among doctors who
treat people positive for HPV, compared to 2- 3%). If
medical personnel use KN95 masks, the infection was 0%.
[43].
All these methods provide enough tissue for the
pathological evaluation. The histopathological result is
classified into CIN1, 2 and 3. CIN1 is also called L-SIL:
mild, moderate dysplasia, located in the basal third, HPV
infection, with an increased regression rate. High-grade
intraepithelial lesions (H-SIL) are subdivided into CIN2
and CIN3. CIN2: moderate dysplasia in two basal thirds,
CIN3: severe dysplasia in two basal thirds, but can affect
the entire epithelium, a situation called carcinoma in situ.
[44].
A study led by Bansal, which included 680 patients,
analyzed the evolution of CIN1 lesions. At 6 months after
diagnosis: 49% regressed spontaneously, 35% had CIN1
lesions, and 7% had a negative outcome. Out of the patients
with negative lesions at 6 months, at the one-year
reassessment: 80% had no lesions, 16% had low-grade
intraepithelial lesions, and 4% had an unfavorable
evolution. In the case of patients with positive lesions at 6
months, at the one-year reassessment: 50% did not present
lesions, 46% CIN1, and 4% evolved negatively [45,46].
The study conducted by Tainio K revealed that CIN2
lesions in half of the cases regress without treatment. This
meta-analysis covering 36 studies and including 3,160
patients showed that at the two-year evaluation: 50%
underwent regression of the lesion, 32% had persistent
lesions, and 18% progressed to CIN3, carcinoma in situ,
invasive cervical carcinoma [47].
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CIN3 lesions may regress spontaneously in 32-47%
of cases or may progress to invasive carcinoma in 1240% of cases [48]. A study conducted by McCredie
evaluated patients at 10 years and 30 years, comparing
the patients' evolutions according to the treatment
undergone. In the case of patients who opted for the
expectant attitude, 20% developed invasive carcinoma
at 10 years, and 31% developed malignant tumor
pathology at 30 years. The patients who opted for the
surgical treatment had an incidence of 0.3% at 10 years
and 0.7% at 30 years [49].
HPV infection can be prevented by vaccination. It is
recommended for all people between 11 and 26 years old
and, in carefully selected cases, for people over 27 years
old. It is recommended for women with a history of
dysplasia and patients with vulgar warts. Vaccination has
no therapeutic effects, but a decrease in the risk of
recurrence has been observed. A meta-analysis performed
by de Villiers EM et al. revealed that the recurrence in
vaccinated patients is 1.9% compared to 5.9% in nonvaccinated patients with CIN2 [50].

Conclusions
Most pre-invasive cervical lesions are caused by the
HPV infection, but not every infection causes the lesions,
so it is not advisable to do it routinely among the young
HPV genotypic population.
The diagnosis of pre-invasive cervical lesions is
eminently made through paraclinical investigations.
Pap smear is an effective method of diagnosis and
screening that must be performed every three years,
performing it earlier does not reduce the risk of mortality
from cervical cancer.
If there is an abnormal Pap smear result, colposcopy is
indicated for a thorough assessment of the squamouscolumn transit area. Pathological lesions with pathological
appearance are leukoplakia, mosaicism, punctures, acetowhite epithelium.
Invasive examinations provide the basis for the
histopathological analysis, thus providing a careful
assessment of the endocervix.
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